MedImmune, LLC
One MedImmune Way
Gaithersburg
Maryland
20878
United States
Tel: 301-398-0000
Fax: 301-398-9000
Website: http://www.medimmune.com/
About MedImmune, LLC
MedImmune is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland with facilities in Pennsylvania, California, Kentucky, the United Kingdom, and the Netherlands. UK facilities include vaccine manufacturing operations in Speke and antibody discovery and research laboratories in Cambridge.
With two marketed products and an advancing pipeline of promising candidates in the areas of infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience, MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees.
352 articles about MedImmune, LLC
-
US FDA Accepts Supplemental Biologics License Application For IMFINZI (Durvalumab) In Locally Advanced, Unresectable Non-Small Cell Lung Cancer
10/17/2017
AstraZeneca and MedImmune today announced that the FDA has accepted a supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) for the treatment of patients with locally advanced.
-
GamaMabs Pharma SA And MedImmune Enter Licensing Agreement To Develop Antibody Drug Conjugate Targeting Cancer
10/10/2017
-
FDA Calls AstraZeneca PLC and MedImmune’s Imfinzi a Breakthrough
8/2/2017
-
Inovio Pharma Provides Update On Launch Of Combination Trial For HPV-Associated Head & Neck Cancer
5/10/2017
-
Sanofi Pasteur Inks $645 Million RSV Deal With AstraZeneca PLC's MedImmune
3/6/2017
-
WuXi AppTec Release: Novel Anti-IL-6 Antibody For Rheumatoid Arthritis From WuXi-MedImmune Joint Venture Receives Clinical Trial Permit (CTP) From CFDA
1/18/2017
-
MedImmune And Abpro Enter Into A Collaborative Agreement For A Novel Bispecific Antibody
11/29/2016
-
MedImmune's Flumist Vaccine Just Got Another Thumbs Down. This Time It's A Pediatricians Group
9/13/2016
-
AstraZeneca PLC Announces MedImmune Layoffs, But Does Not Specify Numbers or Location
7/21/2016
-
MedImmune Release: New CELL Study Presents Groundbreaking Pre-Clinical Work: Developing Immune Therapy To Potentially Treat Serious Influenza A
7/20/2016
-
Genisphere Signs Collaborative Research, Option To License Agreement With MedImmune
6/2/2016
-
TapImmune Announces Phase 2 Ovarian Cancer Trial Study With AstraZeneca PLC/MedImmune And Sloan Kettering Cancer Institute
4/21/2016
-
MedImmune Release: Second Annual Regional Biotech Forum Brings Industry, Academia, Government Together To Raise Region’s Prominence As Top Biotech Hub
4/18/2016
-
Humabs Biomed Reports Regulatory Milestone In MedImmune Partnership
3/23/2016
-
Health Canada, European Medicines Agency, Amgen, Pfizer, AGES, MedImmune And More To Discuss The Challenges In Biosimilar Drug Development At The Upcoming IQPC Summit
3/17/2016
-
Johns Hopkins University And MedImmune Announce Joint Program To Train Ph.D. Students For Careers In Biopharma
3/2/2016
-
Immunocore Starts Clinical Trial With IMCgp100 In Combination With MedImmune Immunotherapies Durvalumab And Tremelimumab
1/20/2016
-
Cepheid Announces Diagnostic Collaboration With MedImmune And COMBACTE To Facilitate Clinical Trials Of New Monoclonal Antibodies To Prevent Serious Infectious Diseases
1/14/2016
-
Rani Therapeutics Announces Collaboration With MedImmune In The Metabolic Disease Field
1/6/2016
-
Unilife Signs Commercial Supply Agreement Wth MedImmune
11/4/2015